[Federal Register Volume 79, Number 81 (Monday, April 28, 2014)]
[Notices]
[Page 23373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-09563]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Patheon 
Pharmaceuticals, Inc.

ACTION: Notice of application with opportunity for comment.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes and 
applicants therefore may file written comments or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.33(a) on or before June 27, 2014.

ADDRESSES: Written comments should be sent via regular or express mail 
to: Drug Enforcement Administration, Attention: DEA Federal Register 
Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 
22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, and dispensers of controlled substances 
(other than final orders in connection with suspension, denial, or 
revocation of registration) has been redelegated to the Deputy 
Assistant Administrator of the DEA Office of Diversion Control 
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR 
part 0, subpart R, App.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
January 8, 2014, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, 
Cincinnati, Ohio 45237, made application by renewal to the DEA to be 
registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), 
a basic class of nonnarcotic controlled substances in schedule I.
    The company plans to manufacture the listed controlled substance 
for distribution to its customers.

    Dated: April 21, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-09563 Filed 4-25-14; 8:45 am]
BILLING CODE 4410-09-P